Ysios Capital Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
11
- Investments
-
61
- Portfolio
-
23
- Exits
-
16
Ysios Capital General Information
Description
Founded in 2008, Ysios Capital is a venture capital investment firm based in San Sebastián, Spain. The firm seeks to invest in early and mid-stage companies operating in biotech, human healthcare, life science and focuses exclusively on innovative therapeutic drugs companies.
Contact Information
Website
www.ysioscapital.com
Year Founded
2008
Investor Status
Actively Seeking New Investments
Trade Association
Spanish Venture Capital Association (ASCRI)
Principles for Responsible Investment (PRI)
Primary Investor Type
Venture Capital
Primary Office
- Avenida de la Libertad
- 25, 4th floor
- 20004 San Sebastian
- Spain
+34 943 00 00 00
Ysios Capital Investments (61)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Mineralys | 08-Jun-2022 | Early Stage VC | 00000 | Drug Discovery | Generating Revenue | |
| 0000000 | 31-May-2022 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 00000 000000 00.0 |
| 000000 000 | 16-Feb-2022 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 00ë0 0000-000000 00.0 |
| 00000000 000000000 | 17-Dec-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 00000 0000 00.0 |
| 000000 000000 | 04-May-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 1 | 00000 000000 00.0 |
| 0000000 | 29-Apr-2021 | 00000 00000 | 000.00 | Biotechnology | Pre-Clinical Trials | 00ë0 0000-000000 00.0 |
| 00000000 000000000 | 20-Apr-2021 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - General | 00ú0 0000í0-0000 00.0 |
| 0000 00000000000 | 22-Mar-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00ë0 0000-000000 00.0 |
| Corwave | 06-Jan-2021 | Later Stage VC | 000.00 | Surgical Devices | Generating Revenue | 00ú0 0000í0-0000 00.0 |
| SparingVision | 21-Oct-2020 | Later Stage VC | 000.00 | Drug Discovery | Generating Revenue | 00000 000000 00.0 |
Ysios Capital Exits (16)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Aura Biosciences | 02-Nov-2021 | IPO | 000.00 |
| 0000 | 30-Jun-2021 | 000 | 00000 |
| 0000 000000000000 | 25-Mar-2021 | 000 | 00000 |
| 0000000 0000000000 | 04-Mar-2021 | 000 00 00000000 | |
| 0000000 | 29-Oct-2020 | 000 | 0000 |
| 00000000000 | 01-Sep-2018 | 000 00 00000000 | |
| 0000-00 | 19-Apr-2018 | 000000000000000000 | 00000 |
| 0000000 0000000000 | 16-Mar-2018 | 000000000000000000 | 00000 |
| TiGenix | 04-Jan-2018 | Merger/Acquisition | 00000 |
| Kala Pharmaceuticals | 20-Jul-2017 | IPO | 0000 |
Ysios Capital Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Ysios Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Ysios Capital Team (28)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Iñigo López-Huerta | Finance Director & Chief Financial Officer | San Sebastian, Spain | |||
| Joël Jean-Mairet Ph.D | Co-Founder & Managing Partner | 00 | 0 | 0 | Barcelona, Spain |
| Julia Salaverría | Co-Founder & Managing Partner | 0 | 0 | San Sebastian, Spain | |
| Karen Wagner Ph.D | Managing Partner | 00 | 0 | 0 | Zurich, Switzerland |
| Cristina Garmendia Mendizábal Ph.D | General Partner & Co-Founding Partner | Barcelona, Spain |
Ysios Capital Co-Investors (110)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Gilde Healthcare Partners | 5 | 0 | 0 |
|
|
| Novo Holdings | 0 | 0 |
|
|
|
| Caixa Capital Risc | 0 | 0 | 0 |
|
|
| EQT Life Sciences | 0 | 0 | 0 |
|
|
| Kurma Partners | 0 | 0 |
|
|